Mad Hedge Biotech and Healthcare Letter April 15, 2025 Fiat Lux Featured Trade: (THE WEIGHT OF EXPECTATIONS) (LLY), (NVO)
Category Archives: Biotech Letter
You know that feeling when you’ve found the perfect restaurant? The food is exquisite, the atmosphere divine, and then you get the bill—and suddenly you’re calculating if selling a kidney is a viable financial strategy. That’s essentially my relationship with Eli Lilly (LLY) right now. Phenomenal company, stellar performance, price tag that makes my wallet […]
Mad Hedge Biotech and Healthcare Letter April 10, 2025 Fiat Lux Featured Trade: (THE $5 BILLION SECRET I SPOTTED IN MY DOCTOR’S WAITING ROOM) (AMGN), (NVO), (LLY), (MRK), (REGN)
Last Tuesday, my orthopedist kept me waiting 40 minutes past my appointment time – just long enough for me to witness what Wall Street’s finest analysts have somehow managed to miss. As I sat thumbing through a dog-eared copy of Golf Digest from 2018, I counted eight different patients called in for Prolia injections. By […]
Mad Hedge Biotech and Healthcare Letter April 8, 2025 Fiat Lux Featured Trade: (YOUR ALL-WEATHER HEALTHCARE FORTRESS) (CI)
I’ve stared down bears in Yellowstone, MiGs over Moscow, and market crashes that would make your financial advisor need therapy. But nothing gets my pulse racing like finding a massively mispriced asset hiding in plain sight. Ladies and gentlemen, I give you Cigna (CI) – the financial equivalent of discovering an abandoned Ferrari with the […]
Mad Hedge Biotech and Healthcare Letter April 3, 2025 Fiat Lux Featured Trade: (MIND THE GAP) (DHR)
Last Thursday, I found myself trapped in an elevator with the former head of R&D at one of Boston’s leading life sciences companies – a guy I’ve known since my Tokyo days in the late ’70s. After we established that neither of us knew how to hack the elevator controls (disappointing, since he has three […]
Mad Hedge Biotech and Healthcare Letter April 1, 2025 Fiat Lux Featured Trade: (HOW ONE SMUG DANE MADE ME EAT MY WORDS) (NVO), (LLY), (ULIHF), (LXRX)
Back in 2008, I found myself in a private dining room at Copenhagen’s Noma restaurant – then barely known outside culinary circles – seated next to a senior Novo Nordisk (NVO) executive who couldn’t stop talking about their early-stage GLP-1 research. “This will change diabetes treatment forever,” he insisted between bites of moss and lichen. […]